Cargando…
Case report: Deep molecular remissions post two separate CD19-targeted chimeric antigen receptor T-cell therapies do not prevent disease from relapsing in Philadelphia chromosome-positive acute lymphoblastic leukemia
Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) is an aggressive B-cell malignancy. The management of a relapsed Ph+ ALL patient is challenging. Currently, either allogeneic stem cell transplant (allo-SCT) or CD19-targeted chimeric antigen receptor T-cell (CAR T-cell) are usu...
Autores principales: | Tang, Yu, Fei, Xiaoming, Yu, Xianqiu, Cao, Jiang, Wang, Lixia, Lei, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656679/ https://www.ncbi.nlm.nih.gov/pubmed/38023231 http://dx.doi.org/10.3389/fonc.2023.1251738 |
Ejemplares similares
-
Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia
por: Shah, Gaurav, et al.
Publicado: (2019) -
Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kawano, Noriaki, et al.
Publicado: (2020) -
Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report
por: Yang, Mianzeng, et al.
Publicado: (2020) -
Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports
por: Zhu, Yang-min, et al.
Publicado: (2016) -
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
por: Davis, Tyler, et al.
Publicado: (2013)